> Details
Hauke, Jan;
Horvath, Judit;
Groß, Eva;
Gehrig, Andrea;
Honisch, Ellen;
Hackmann, Karl;
Schmidt, Gunnar;
Arnold, Norbert;
Faust, Ulrike;
Sutter, Christian;
Hentschel, Julia;
Wang‐Gohrke, Shan;
Smogavec, Mateja;
Weber, Bernhard H. F.;
Weber‐Lassalle, Nana;
Weber‐Lassalle, Konstantin;
Borde, Julika;
Ernst, Corinna;
Altmüller, Janine;
Volk, Alexander E.;
Thiele, Holger;
Hübbel, Verena;
Nürnberg, Peter;
Keupp, Katharina;
[...]
Gene panel testing of 5589 BRCA1/2‐negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer
Sharing
Reference
management
Direct link
Bookmarks
Remove from
bookmarks
Share this by email
Share this on Twitter
Share this on Facebook
Share this on Whatsapp
- Media type: E-Article
- Title: Gene panel testing of 5589 BRCA1/2‐negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer
- Contributor: Hauke, Jan; Horvath, Judit; Groß, Eva; Gehrig, Andrea; Honisch, Ellen; Hackmann, Karl; Schmidt, Gunnar; Arnold, Norbert; Faust, Ulrike; Sutter, Christian; Hentschel, Julia; Wang‐Gohrke, Shan; Smogavec, Mateja; Weber, Bernhard H. F.; Weber‐Lassalle, Nana; Weber‐Lassalle, Konstantin; Borde, Julika; Ernst, Corinna; Altmüller, Janine; Volk, Alexander E.; Thiele, Holger; Hübbel, Verena; Nürnberg, Peter; Keupp, Katharina; [...]
-
imprint:
Wiley, 2018
- Published in: Cancer Medicine
- Language: English
- DOI: 10.1002/cam4.1376
- ISSN: 2045-7634
- Keywords: Cancer Research ; Radiology, Nuclear Medicine and imaging ; Oncology
- Origination:
- Footnote:
- Description: <jats:title>Abstract</jats:title><jats:p>The prevalence of germ line mutations in non‐<jats:italic><jats:styled-content style="fixed-case">BRCA</jats:styled-content>1/2</jats:italic> genes associated with hereditary breast cancer (<jats:styled-content style="fixed-case">BC</jats:styled-content>) is low, and the role of some of these genes in <jats:styled-content style="fixed-case">BC</jats:styled-content> predisposition and pathogenesis is conflicting. In this study, 5589 consecutive <jats:styled-content style="fixed-case">BC</jats:styled-content> index patients negative for pathogenic <jats:italic><jats:styled-content style="fixed-case">BRCA</jats:styled-content>1/2</jats:italic> mutations and 2189 female controls were screened for germ line mutations in eight cancer predisposition genes (<jats:italic><jats:styled-content style="fixed-case">ATM</jats:styled-content></jats:italic>,<jats:italic> <jats:styled-content style="fixed-case">CDH</jats:styled-content>1</jats:italic>,<jats:italic> <jats:styled-content style="fixed-case">CHEK</jats:styled-content>2</jats:italic>,<jats:italic> <jats:styled-content style="fixed-case">NBN</jats:styled-content></jats:italic>,<jats:italic> <jats:styled-content style="fixed-case">PALB</jats:styled-content>2</jats:italic>,<jats:italic> <jats:styled-content style="fixed-case">RAD</jats:styled-content>51C</jats:italic>,<jats:italic> <jats:styled-content style="fixed-case">RAD</jats:styled-content>51D,</jats:italic> and <jats:italic><jats:styled-content style="fixed-case">TP</jats:styled-content>53</jats:italic>). All patients met the inclusion criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for germ line testing. The highest mutation prevalence was observed in the <jats:italic><jats:styled-content style="fixed-case">CHEK</jats:styled-content>2</jats:italic> gene (2.5%), followed by <jats:italic><jats:styled-content style="fixed-case">ATM</jats:styled-content></jats:italic> (1.5%) and <jats:italic><jats:styled-content style="fixed-case">PALB</jats:styled-content>2</jats:italic> (1.2%). The mutation prevalence in each of the remaining genes was 0.3% or lower. Using Exome Aggregation Consortium control data, we confirm significant associations of heterozygous germ line mutations with <jats:styled-content style="fixed-case">BC</jats:styled-content> for <jats:italic><jats:styled-content style="fixed-case">ATM</jats:styled-content></jats:italic> (<jats:styled-content style="fixed-case">OR</jats:styled-content>: 3.63, 95%<jats:styled-content style="fixed-case">CI</jats:styled-content>: 2.67–4.94), <jats:italic><jats:styled-content style="fixed-case">CDH</jats:styled-content>1</jats:italic> (<jats:styled-content style="fixed-case">OR</jats:styled-content>: 17.04, 95%<jats:styled-content style="fixed-case">CI</jats:styled-content>: 3.54–82), <jats:italic><jats:styled-content style="fixed-case">CHEK</jats:styled-content>2</jats:italic> (<jats:styled-content style="fixed-case">OR</jats:styled-content>: 2.93, 95%<jats:styled-content style="fixed-case">CI</jats:styled-content>: 2.29–3.75), <jats:italic><jats:styled-content style="fixed-case">PALB</jats:styled-content>2</jats:italic> (<jats:styled-content style="fixed-case">OR</jats:styled-content>: 9.53, 95%<jats:styled-content style="fixed-case">CI</jats:styled-content>: 6.25–14.51), and <jats:italic><jats:styled-content style="fixed-case">TP</jats:styled-content>53</jats:italic> (<jats:styled-content style="fixed-case">OR</jats:styled-content>: 7.30, 95%<jats:styled-content style="fixed-case">CI</jats:styled-content>: 1.22–43.68). <jats:italic><jats:styled-content style="fixed-case">NBN</jats:styled-content></jats:italic> germ line mutations were not significantly associated with <jats:styled-content style="fixed-case">BC</jats:styled-content> risk (<jats:styled-content style="fixed-case">OR</jats:styled-content>:1.39, 95%<jats:styled-content style="fixed-case">CI</jats:styled-content>: 0.73–2.64). Due to their low mutation prevalence, the <jats:italic><jats:styled-content style="fixed-case">RAD</jats:styled-content>51C</jats:italic> and <jats:italic><jats:styled-content style="fixed-case">RAD</jats:styled-content>51D</jats:italic> genes require further investigation. Compared with control datasets, predicted damaging rare missense variants were significantly more prevalent in <jats:italic><jats:styled-content style="fixed-case">CHEK</jats:styled-content>2</jats:italic> and <jats:italic><jats:styled-content style="fixed-case">TP</jats:styled-content>53</jats:italic> in <jats:styled-content style="fixed-case">BC</jats:styled-content> index patients. Compared with the overall sample, only <jats:italic><jats:styled-content style="fixed-case">TP</jats:styled-content>53</jats:italic> mutation carriers show a significantly younger age at first <jats:styled-content style="fixed-case">BC</jats:styled-content> diagnosis. We demonstrate a significant association of deleterious variants in the <jats:italic><jats:styled-content style="fixed-case">CHEK</jats:styled-content>2</jats:italic>,<jats:italic> <jats:styled-content style="fixed-case">PALB</jats:styled-content>2,</jats:italic> and <jats:italic><jats:styled-content style="fixed-case">TP</jats:styled-content>53</jats:italic> genes with bilateral <jats:styled-content style="fixed-case">BC</jats:styled-content>. Both, <jats:italic><jats:styled-content style="fixed-case">ATM</jats:styled-content></jats:italic> and <jats:italic><jats:styled-content style="fixed-case">CHEK</jats:styled-content>2</jats:italic>, were negatively associated with triple‐negative breast cancer (<jats:styled-content style="fixed-case">TNBC</jats:styled-content>) and estrogen receptor (<jats:styled-content style="fixed-case">ER</jats:styled-content>)‐negative tumor phenotypes. A particularly high <jats:italic><jats:styled-content style="fixed-case">CHEK</jats:styled-content>2</jats:italic> mutation prevalence (5.2%) was observed in patients with human epidermal growth factor receptor 2 (<jats:styled-content style="fixed-case">HER</jats:styled-content>2)‐positive tumors.</jats:p>
- Access State: Open Access